Empowering Your Employees in the Face of Modern Workplace Stresses

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

For an organization to find long-term success, it requires a commitment from all parties. Employers have to commit to employees and vice-versa. But how can organizations get it right in a world of overworked and stressed-out staff members?

Joining I Don’t Care to talk about this is employee wellness and engagement guru Lorna Borenstein, CEO and founder of Grokker. She had the vision to start the employee wellbeing company after working for big tech companies like eBay and Yahoo and realizing the employee-employer dynamic needed to shift.

Borenstein explained the transformation. “The agreement used to be that a company would pay you well, and you wouldn’t bring your problems to work. Now, younger generations aren’t making money like their parents, and they were raised by people who gave them a voice. They have no blind loyalty and expect more.”

Grokker recently released its 2021 Working Americans’ State of Stress Report finding that 80% of workers are stressed out. Younger generations have the highest levels. This stress impacts their lives at work and home.

Borenstein said that for employees to be engaged requires a sense of purpose, belonging, and balance. Most companies do well on the first two, but the balance is harder. The pandemic, in some ways, had made balance more possible. “The good news is that companies woke up and realized their people are their business,” she said.

That awakening led to the Human Connection Movement, a philosophy that Borenstein writes about in her book, It’s Personal: The Business Case for Caring. “Employees are saying you need to care about me.”

Borenstein also discussed examples of the changing paradigm with clients like CVS Health. She noted, “Now 85% of employers consider employee wellbeing to be part of their business strategy; so, it’s culture as strategy.”

Listen to Previous Episodes of MarketScale’s I Don’t Care Right Here!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More